BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Jain A, Jahagirdar D, Nilendu P, Sharma NK. Molecular approaches to potentiate cisplatin responsiveness in carcinoma therapeutics. Expert Review of Anticancer Therapy 2017;17:815-25. [DOI: 10.1080/14737140.2017.1356231] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Li J, Eu JQ, Kong LR, Wang L, Lim YC, Goh BC, Wong ALA. Targeting Metabolism in Cancer Cells and the Tumour Microenvironment for Cancer Therapy. Molecules 2020;25:E4831. [PMID: 33092283 DOI: 10.3390/molecules25204831] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
2 Li J, Pan C, Boese AC, Kang J, Umano AD, Magliocca KR, Yang W, Zhang Y, Lonial S, Jin L, Kang S. DGKA Provides Platinum Resistance in Ovarian Cancer Through Activation of c-JUN-WEE1 Signaling. Clin Cancer Res 2020;26:3843-55. [PMID: 32341033 DOI: 10.1158/1078-0432.CCR-19-3790] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
3 Bandolik JJ, Hamacher A, Schrenk C, Weishaupt R, Kassack MU. Class I-Histone Deacetylase (HDAC) Inhibition is Superior to pan-HDAC Inhibition in Modulating Cisplatin Potency in High Grade Serous Ovarian Cancer Cell Lines. Int J Mol Sci 2019;20:E3052. [PMID: 31234549 DOI: 10.3390/ijms20123052] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 6.3] [Reference Citation Analysis]
4 Ye J, Sun D, Yu Y, Yu J. Osthole resensitizes CD133+ hepatocellular carcinoma cells to cisplatin treatment via PTEN/AKT pathway. Aging (Albany NY) 2020;12:14406-17. [PMID: 32673286 DOI: 10.18632/aging.103484] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
5 Aydemir I, Turkoz Uluer E, Korkmaz O, Tuglu MI, Inan S. Adjuvant effects of chemotherapeutics and Metformin on MFE-319 endometrial carcinoma cell line. Rom J Morphol Embryol 2020;61:707-14. [PMID: 33817712 DOI: 10.47162/RJME.61.3.09] [Reference Citation Analysis]
6 Okon E, Luszczki JJ, Kukula-Koch W, Halasa M, Jarzab A, Khurelbat D, Stepulak A, Wawruszak A. Synergistic or Additive Pharmacological Interactions between Magnoflorine and Cisplatin in Human Cancer Cells of Different Histological Origin. Int J Mol Sci 2020;21:E2848. [PMID: 32325867 DOI: 10.3390/ijms21082848] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
7 Ashrafizadeh M, Zarrabi A, Hushmandi K, Kalantari M, Mohammadinejad R, Javaheri T, Sethi G. Association of the Epithelial-Mesenchymal Transition (EMT) with Cisplatin Resistance. Int J Mol Sci 2020;21:E4002. [PMID: 32503307 DOI: 10.3390/ijms21114002] [Cited by in Crossref: 38] [Cited by in F6Publishing: 46] [Article Influence: 19.0] [Reference Citation Analysis]
8 Utama K, Khamto N, Meepowpan P, Aobchey P, Kantapan J, Sringarm K, Roytrakul S, Sangthong P. Effects of 2',4'-Dihydroxy-6'-methoxy-3',5'-dimethylchalcone from Syzygium nervosum Seeds on Antiproliferative, DNA Damage, Cell Cycle Arrest, and Apoptosis in Human Cervical Cancer Cell Lines. Molecules 2022;27:1154. [PMID: 35208945 DOI: 10.3390/molecules27041154] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Jahagirdar D, Purohit S, Sharma NK. Combinatorial Use of DNA Ligase Inhibitor L189 and Temozolomide Potentiates Cell Growth Arrest in HeLa. CCTR 2019;15:65-73. [DOI: 10.2174/1573394714666180216150332] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
10 Zaal EA, Berkers CR. The Influence of Metabolism on Drug Response in Cancer. Front Oncol 2018;8:500. [PMID: 30456204 DOI: 10.3389/fonc.2018.00500] [Cited by in Crossref: 80] [Cited by in F6Publishing: 73] [Article Influence: 20.0] [Reference Citation Analysis]
11 Reyes ME, de La Fuente M, Hermoso M, Ili CG, Brebi P. Role of CC Chemokines Subfamily in the Platinum Drugs Resistance Promotion in Cancer. Front Immunol 2020;11:901. [PMID: 32499779 DOI: 10.3389/fimmu.2020.00901] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
12 Mora Y, Reyes ME, Zanella L, Mora B, Buchegger K, Ili C, Brebi P. Resistance to platinum-based cancer drugs: a special focus on epigenetic mechanisms. Pharmacogenomics 2021. [PMID: 34281355 DOI: 10.2217/pgs-2021-0020] [Reference Citation Analysis]